StockNews.com Downgrades DENTSPLY SIRONA (NASDAQ:XRAY) to Hold

May 16, 2023

DENTSPLY SIRONA (NASDAQ:XRAY - Get Rating) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday.

XRAY has been the subject of several other research reports. UBS Group increased their price target on DENTSPLY SIRONA from $43.00 to $46.00 in a research note on Friday, May 5th. Robert W. Baird raised their target price on DENTSPLY SIRONA from $36.00 to $46.00 in a research note on Thursday, May 4th. The Goldman Sachs Group raised their target price on DENTSPLY SIRONA from $34.00 to $39.00 and gave the stock a "neutral" rating in a research note on Wednesday, March 1st. Morgan Stanley raised their target price on DENTSPLY SIRONA from $39.00 to $45.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 19th. Finally, Stifel Nicolaus raised their target price on DENTSPLY SIRONA from $37.00 to $41.00 in a research note on Thursday, May 4th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $42.13.

DENTSPLY SIRONA stock opened at $39.13 on Wednesday. The company has a market capitalization of $8.31 billion, a PE ratio of 14.10, a P/E/G ratio of 2.22 and a beta of 0.93. The stock has a 50-day moving average price of $39.86 and a two-hundred day moving average price of $36.54. The company has a current ratio of 1.41, a quick ratio of 0.93 and a debt-to-equity ratio of 0.51. DENTSPLY SIRONA has a 12 month low of $26.48 and a 12 month high of $43.24.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Rating) last issued its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.05. The company had revenue of $978.00 million during the quarter, compared to analysts' expectations of $938.16 million. DENTSPLY SIRONA had a positive return on equity of 8.65% and a negative net margin of 26.41%. The business's quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. Analysts expect that DENTSPLY SIRONA will post 1.91 EPS for the current year.

In other news, Director Eric Brandt sold 6,200 shares of the firm's stock in a transaction that occurred on Tuesday, May 2nd. The stock was sold at an average price of $42.17, for a total value of $261,454.00. Following the transaction, the director now owns 44,902 shares in the company, valued at $1,893,517.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.74% of the company's stock.

A number of large investors have recently modified their holdings of the stock. MetLife Investment Management LLC lifted its holdings in DENTSPLY SIRONA by 23.1% during the first quarter. MetLife Investment Management LLC now owns 59,453 shares of the medical instruments supplier's stock worth $2,926,000 after acquiring an additional 11,156 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in DENTSPLY SIRONA by 6.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 29,250 shares of the medical instruments supplier's stock worth $1,440,000 after buying an additional 1,811 shares during the last quarter. Raymond James Trust N.A. increased its position in DENTSPLY SIRONA by 61.7% in the first quarter. Raymond James Trust N.A. now owns 7,042 shares of the medical instruments supplier's stock worth $346,000 after buying an additional 2,687 shares during the last quarter. Dimensional Fund Advisors LP increased its position in DENTSPLY SIRONA by 6.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,833,372 shares of the medical instruments supplier's stock worth $90,243,000 after buying an additional 117,571 shares during the last quarter. Finally, Sei Investments Co. increased its position in DENTSPLY SIRONA by 18.9% in the first quarter. Sei Investments Co. now owns 468,759 shares of the medical instruments supplier's stock worth $23,090,000 after buying an additional 74,629 shares during the last quarter. Institutional investors own 98.52% of the company's stock.

Dentsply Sirona, Inc engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider DENTSPLY SIRONA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.

While DENTSPLY SIRONA currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.